5000 Participants Needed

CD388 Injection for Flu Prevention

(NAVIGATE Trial)

Recruiting at 56 trial locations
Ho
Overseen ByHead of Clinical Operations
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Do I have to stop taking my current medications to join the trial?

The trial information does not specify if you need to stop taking your current medications. However, you should discuss your medications with the study team to ensure they don't interfere with the trial.

What data supports the effectiveness of the drug CD388 Injection for flu prevention?

Research on similar treatments shows that using adjuvants (substances that enhance the body's immune response to an antigen) can improve the effectiveness of flu vaccines. For example, the use of adjuvants like CpG 1018 in vaccines has been shown to provide strong protection against flu in animal studies.12345

How is the drug CD388 unique for flu prevention?

CD388 is unique because it targets CD38, a molecule involved in immune cell activation and signaling, which is not a common target for flu prevention. This approach may offer a novel mechanism compared to traditional flu vaccines that typically target viral proteins.678910

What is the purpose of this trial?

The purpose of this study is to evaluate the effectiveness of CD388 in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, and to select a dose of CD388 that is effective in preventing the same, when administered as a single dose via 3 subcutaneous (SQ) injections to adult participants in stable health, and to evaluate the safety and tolerability of CD388, as compared to placebo.

Research Team

ND

Nicole Davarpanah, MD, JD

Principal Investigator

Cidara Therapeutics Inc.

Eligibility Criteria

This trial is for healthy adults who are not at high risk of complications from the flu. Participants will receive a single dose of CD388 or a placebo to test its effectiveness in preventing influenza.

Inclusion Criteria

Must be able to read, understand, and complete questionnaires in the electronic diary, work with smartphones/tablets/computers, and adhere to study protocol
Body mass index (BMI) of 18.0 kg/m^2 to 35.0 kg/m^2
Willing and able to provide written informed consent and comply with scheduled visits, laboratory tests, and other study procedures
See 5 more

Exclusion Criteria

I do not have any serious or unstable health conditions.
I have been in close contact with someone who has flu or COVID-19 recently.
I have not donated blood recently.
See 14 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single dose of CD388 via 3 subcutaneous injections

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

28 weeks
Multiple visits (in-person and virtual) including Day 8, Day 29, Day 85, and Day 197

Treatment Details

Interventions

  • CD388
Trial Overview The study is testing CD388, given as three subcutaneous injections in one dose, against a placebo to see if it can prevent symptomatic lab-confirmed flu infections.
Participant Groups
4Treatment groups
Experimental Treatment
Placebo Group
Group I: CD388 Medium DoseExperimental Treatment1 Intervention
Participants are randomized to receive a medium dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
Group II: CD388 Low DoseExperimental Treatment1 Intervention
Participants are randomized to receive a low dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
Group III: CD388 High DoseExperimental Treatment1 Intervention
Participants are randomized to receive a high dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
Group IV: PlaceboPlacebo Group1 Intervention
Participants are randomized to receive placebo by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Cidara Therapeutics Inc.

Lead Sponsor

Trials
12
Recruited
7,400+

Findings from Research

CD38 is a promising target for anticancer therapy, particularly in treating multiple myeloma and immunoglobulin light-chain amyloidosis, with several anti-CD38 antibodies like daratumumab and isatuximab already approved by the FDA.
Beyond cancer, CD38 is implicated in various diseases, including autoimmune disorders and viral infections, suggesting its potential as a therapeutic target and biomarker in conditions like transplant rejection and systemic lupus erythematosus.
Targeting CD38 in Neoplasms and Non-Cancer Diseases.Szlasa, W., Czarny, J., Sauer, N., et al.[2022]

References

A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. [2013]
The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. [2022]
A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice. [2022]
Intranasal Immunization Using CTA1-DD as a Mucosal Adjuvant for an Inactivated Influenza Vaccine. [2019]
Injectable Excipients as Novel Influenza Vaccine Adjuvants. [2020]
Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. [2021]
Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. [2020]
Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse. [2021]
Targeting CD38 in Neoplasms and Non-Cancer Diseases. [2022]
The role of CD38 in HIV infection. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security